The logic behind marine pharmacognosy rests on a simple evolutionary principle. Organisms living in extreme or highly competitive environments, such as coral reefs crowded with rivals or the deep sea where pressure is crushing and light is absent, often evolve unique chemical compounds as survival tools. Some of these molecules deter predators, others help an organism compete for space on a crowded reef, and still others allow cells to function under conditions that would kill most life on Earth. For drug hunters, this chemical arms race represents an enormous library of biologically active molecules that have already been tested by millions of years of natural selection. Unlike a randomly synthesized compound, a marine natural product has a demonstrated capacity to interact with living systems, which makes it a promising starting point for drug development.

The review, authored by Shivani Verma, Somesh Saxena, and corresponding author Raj Kumari Kataria, was assembled from peer-reviewed literature retrieved from three major scientific databases: Scopus, PubMed, and Web of Science. Rather than attempting an exhaustive catalog of every marine compound ever described, the authors deliberately focused on the modern tools that are transforming how discovery happens. High-throughput screening, which enables researchers to rapidly test large numbers of compounds for biological activity, features prominently in their analysis, as do computational biology and genomics. The review also narrows its attention to two detailed case studies of marine-derived drugs that have reached the clinic, trabectedin and vidarabine, using them to illustrate both the promise and the practical difficulties of translating ocean chemistry into medicine.

Trabectedin stands as one of the most celebrated success stories in the field. Derived originally from the sea squirt Ecteinascidia turbinata, a tunicate found in Caribbean and Mediterranean waters, the compound was developed into an approved treatment for soft tissue sarcoma and relapsed ovarian cancer in several regions of the world. Its journey from a slow-growing marine invertebrate to a pharmacy shelf illustrates a recurring theme in marine drug development: the organism that produces a valuable compound is often rare, slow to reproduce, or difficult to cultivate, which makes extracting enough material directly from nature impractical. Solutions have included aquaculture, partial chemical synthesis, and microbial production routes, each of which carries its own technical and economic trade-offs that the review examines in detail.

Vidarabine tells a different but equally instructive story. Isolated from a marine sponge-associated microorganism, this nucleoside analog became one of the early antiviral agents used against herpes virus infections, demonstrating that marine sources can yield not only anticancer agents but also compounds active against viruses. Together, the two case studies span the therapeutic spectrum that marine natural products have touched so far, from cytotoxic molecules that kill cancer cells to antivirals that interfere with viral replication. The review uses this breadth to argue that the ocean’s medicine cabinet is not a narrow specialty but a genuinely diverse source of pharmacological leads, one that includes alkaloids, peptides, nucleosides, and many other chemical classes.

The technological toolkit driving current discovery has changed dramatically from the era when marine drug hunting meant dredging samples and testing crude extracts by hand. High-throughput screening now allows thousands of compounds to be evaluated against disease targets in days rather than months. Computational biology adds the ability to model how a candidate molecule will interact with proteins and receptors before it is ever synthesized in quantity, narrowing the pipeline early and saving resources. Genomic sequencing of marine organisms reveals the biosynthetic gene clusters responsible for producing their chemical weapons, which means researchers can identify promising pathways even in microbes that cannot yet be grown in the laboratory. Synthetic biology then offers a route to reproducing those molecules in tractable host organisms, bypassing the need to harvest the original source.

Yet the review is candid about the barriers that continue to slow the field. Many marine compounds occur naturally only in minute quantities, often as fractions of a percent of the organism’s body mass, which makes direct extraction costly and frequently impossible at commercial scale. The supply problem has historically killed otherwise promising drug candidates, a phenomenon so common in natural products research that it has shaped entire strategies around total synthesis and analog development. Beyond economics, overharvesting poses serious sustainability and conservation risks. A sponge that took decades to grow cannot be stripped from a reef without ecological consequences, and deep-sea ecosystems in particular are fragile, slow to recover, and still poorly understood. The authors argue that these constraints are not peripheral concerns but central design problems for the next generation of marine drug discovery.

The review’s answer to this tension is a firm insistence that sustainable sourcing must sit at the heart of marine pharmacognosy going forward. Synthetic production in the laboratory or in engineered microbes can decouple drug supply from ecosystem damage, while environmentally responsible harvesting practices can protect the organisms and habitats that remain the field’s inspiration. The authors also highlight deep-sea exploration and green chemistry as strategies that can expand the search for new compounds without repeating the extractive mistakes of the past. Green chemistry, which emphasizes processes that reduce or eliminate hazardous substances, aligns naturally with a field whose raw materials come from ecosystems that cannot tolerate industrial abuse. The overarching message is that drug discovery and marine biodiversity protection need not be in conflict; with advanced technology and genuine conservation commitments, both goals can be pursued together.

The urgency of that dual mandate is sharpened by the public health challenges the review identifies, above all antibiotic resistance. As resistance to existing antibiotics spreads worldwide, the need for novel chemical scaffolds with mechanisms of action unlike current drugs has become acute, and marine microorganisms in particular are known producers of antimicrobial compounds. The review frames marine pharmacognosy as a contributor to addressing this and other urgent health threats, provided that the pipeline from ocean organism to approved medicine can be made faster, cheaper, and cleaner. Whether the next trabectedin or vidarabine emerges from a coral reef sponge, a deep-sea microbe, or a fermentation tank programmed with sponge genes will depend on how well the field integrates the tools and the ethics it now has at its disposal.

For now, the review by Verma, Saxena, and Kataria serves as both a status report and a warning. The ocean has already given medicine drugs that fight cancer and viral infection, and the diversity of its reefs, sediments, and microbial communities suggests that this is only the beginning. But the same ecosystems that generate these molecules are under pressure from warming waters, pollution, and habitat destruction, meaning the window for discovery may be closing even as the science accelerates. The authors’ conclusion is that the future of marine pharmacognosy depends on treating the ocean not as a mine to be emptied but as a living library to be read carefully, with every extraction weighed against the health of the source. In that framing, conservation is not an obstacle to the next breakthrough but the condition that makes it possible.

Subject of Research: Marine pharmacognosy and the discovery of bioactive drug compounds from ocean organisms

Article Title: Review surveys the ocean's medicine cabinet, from cancer-fighting alkaloids to antiviral compounds

Article References: Review surveys the ocean's medicine cabinet, from cancer-fighting alkaloids to antiviral compounds. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: marine pharmacognosy, drug discovery, trabectedin, vidarabine, marine natural products, high-throughput screening, genomics, synthetic biology, sustainability, ocean biodiversity, antibiotic resistance, deep-sea exploration

Myxoid leiomyosarcoma, often abbreviated mLMS, is a rare morphological variant of leiomyosarcoma, a cancer arising from smooth muscle tissue. What distinguishes the myxoid variant is its abundant gelatinous stroma, a matrix that separates the neoplastic smooth muscle cells and gives the tumor a deceptively bland appearance under the microscope. While the uterus is the most common primary site, extra-uterine occurrences involving the retroperitoneum, the intra-abdominal cavity, and soft tissues are exceedingly rare. Population-based data confirm this extreme rarity and identify elderly females as the demographic most frequently affected, with the uterus representing the predominant primary site among myxosarcoma subtypes. Because so few cases exist, the clinicopathological behavior of extra-uterine disease remains poorly characterized, and management protocols are largely extrapolated from data on uterine leiomyosarcoma.

The prognosis of myxoid leiomyosarcoma is a subject of genuine scientific debate, and the disagreement is striking. Some clinical series report a highly aggressive course, with five-year overall survival as low as 11.1 percent, driven by a strong propensity for local recurrence and distant metastasis. In contrast, a Norwegian population-based study reported five-year survival approaching 73 percent, slightly more favorable than conventional leiomyosarcoma, and another investigation documented recurrence in only five of twelve cases over follow-up periods ranging from three to nine years. Researchers believe this discrepancy likely reflects heterogeneity in the diagnostic criteria applied across studies and, more fundamentally, underlying molecular diversity within the entity. Large-scale molecular profiling of uterine sarcomas has underscored that molecular classification refines both diagnosis and prognosis, suggesting that the apparent clinical variability of myxoid leiomyosarcoma may mask several biologically distinct subtypes awaiting precise definition.

Diagnostically, the tumor presents formidable challenges because its morphological and radiological features overlap with a spectrum of benign and malignant myxoid lesions, including myxoid leiomyoma, aggressive angiomyxoma, and low-grade endometrial stromal sarcoma. The myxoid matrix imparts low-attenuation characteristics on computed tomography and heterogeneous signal on other imaging modalities, frequently mimicking benign cystic structures or other soft tissue tumors, which renders imaging insufficient for definitive characterization. In the newly reported case, a contrast-enhanced abdominal CT scan revealed a large, poorly enhanced, heterogeneous soft tissue mass measuring 11.8 centimeters in the left peritoneal space, together with a separate complex cystic-solid lesion measuring 5.8 centimeters in the left lower abdomen. The presence of two spatially distinct lesions raised the possibility of a primary intra-abdominal neoplasm with a satellite deposit or multifocal disease, and a CT-guided core needle biopsy could only suggest an atypical myxoid neoplasm without definitive classification.

Definitive answers came only after surgical excision, performed for concurrent diagnosis and treatment. Gross examination of the resected specimen revealed a multilobulated mass with a gelatinous cut surface and a small adjacent satellite nodule. Under the microscope, the tumor showed a spindle cell proliferation with mild nuclear atypia and high mitotic activity, with 26 mitoses counted per ten high-power fields, all embedded within abundant myxoid stroma. Immunohistochemistry, the technique of using antibodies to detect specific proteins in tissue sections, played a pivotal role. The tumor cells displayed strong and diffuse positivity for desmin, a marker of muscle lineage, but were negative for SMA, h-Caldesmon, and SMMHC, a pattern consistent with the incomplete smooth muscle differentiation profile characteristic of myxoid leiomyosarcoma. Unlike conventional leiomyosarcoma, the myxoid variant frequently shows reduced or absent reactivity for these markers while retaining desmin in most cases, an inconsistency that can easily mislead observers unfamiliar with the entity.

The immunophenotype grew more complicated still. The tumor co-expressed the estrogen and progesterone receptors along with CD10 and Cyclin D1, a combination that prompted consideration of endometrial stromal sarcoma, another uterine mesenchymal malignancy with which myxoid leiomyosarcoma is frequently confused. However, the retention of desmin positivity, the morphological context, and subsequent molecular results argued against that diagnosis. Crucially, immunohistochemistry also revealed strong and diffuse nuclear overexpression of the PLAG1 protein, a finding that prompted a dedicated molecular workup. Overexpression of the MDM2 protein was identified as well, but fluorescence in situ hybridization, or FISH, confirmed a PLAG1 break-apart signal consistent with PLAG1 gene rearrangement while demonstrating an absence of MDM2 gene amplification. That combination effectively excluded well-differentiated and dedifferentiated liposarcoma, tumors that can morphologically overlap with myxoid lesions and that are defined by MDM2 amplification.

The PLAG1 rearrangement carries substantial diagnostic weight. Previous molecular studies have identified PLAG1 gene rearrangement in approximately 25 percent of uterine myxoid leiomyosarcoma cases, and it represents a highly specific biomarker that distinguishes this entity from ZC3H7B-BCOR high-grade endometrial stromal sarcoma and from myxoid inflammatory myofibroblastic tumor. Importantly, strong and diffuse nuclear PLAG1 immunoexpression, as observed in this patient, reliably identifies tumors harboring the rearrangement and serves as a practical triage tool before confirmatory FISH is performed. Integrating the histomorphological pattern, the immunophenotype, and the molecular findings, the clinical team rendered a definitive diagnosis of myxoid leiomyosarcoma harboring PLAG1 gene rearrangement, an example of how modern pathology increasingly depends on layered molecular evidence rather than morphology alone.

Of particular clinical significance is the patient’s prior laparoscopic myomectomy, performed two years earlier for a 13-centimeter submucosal uterine myoma. Surgical oncology literature emphasizes that myomectomy is strictly indicated for benign leiomyomas, and that inadvertent surgery on an occult leiomyosarcoma carries the risk of intraperitoneal tumor dissemination even in the absence of morcellation, the mechanical fragmentation of tissue during minimally invasive removal. Tumor cells have been detected in peritoneal fluid following myomectomy alone. The multilesional intraperitoneal distribution observed in this patient, with two spatially separate masses and an adjacent satellite nodule, raises strong suspicion that iatrogenic peritoneal seeding secondary to the prior myomectomy may have contributed to the tumor’s distribution. The authors of the report stress that any leiomyosarcoma diagnosis arising after a prior myomectomy warrants complete surgical re-evaluation, including hysterectomy, and close surveillance for intraperitoneal disease, and that the case reinforces the critical need for accurate preoperative differentiation between benign leiomyoma and leiomyosarcoma, particularly in younger patients with large or atypical uterine masses.

Treatment and outcomes in this case offer a measure of reassurance alongside the cautionary elements. The patient recovered smoothly after her tumor excision, experiencing only transient abdominal distention, and was discharged on the tenth postoperative day. At six-month outpatient follow-up she remained completely asymptomatic, with no clinical or radiological evidence of recurrence. Complete surgical excision with negative margins remains the cornerstone of curative-intent management for localized myxoid leiomyosarcoma, since standardized treatment guidelines for the rare entity remain elusive. For advanced disease, systemic therapy is an important consideration given the high rates of metastatic failure following resection. Doxorubicin has long been the standard first-line agent for metastatic leiomyosarcoma, but the LMS-04 Phase III randomized controlled trial demonstrated that combining doxorubicin with trabectedin significantly improved progression-free survival compared with doxorubicin monotherapy in metastatic or unresectable disease, an advance that should inform treatment planning for patients with unresectable or metastatic myxoid leiomyosarcoma.

The broader lessons of this single case extend well beyond one patient’s chart. The combination of an incomplete smooth muscle immunophenotype, strong diffuse nuclear PLAG1 expression, and confirmatory FISH proved instrumental in establishing a definitive molecular diagnosis that morphology and imaging alone could never deliver. The authors argue that comprehensive molecular workup, including PLAG1 immunohistochemistry and FISH, should be considered in all myxoid intra-abdominal tumors, particularly in patients with a prior history of uterine surgery. At the same time, the prognostic significance of PLAG1 rearrangement itself remains unresolved and, according to the report, warrants dedicated prospective investigation. For clinicians, the case is a reminder that the gelatinous, deceptively bland tumors encountered in the abdomen may conceal a malignant smooth muscle origin, and for surgeons and patients contemplating fibroid removal, it underscores the enduring importance of rigorous preoperative risk stratification before any uterine operation is undertaken.

Subject of Research: Intra-abdominal myxoid leiomyosarcoma with PLAG1 gene rearrangement following prior laparoscopic myomectomy

Article Title: Intra‐Abdominal Myxoid Leiomyosarcoma With PLAG1 Gene Rearrangement Following Prior Laparoscopic Myomectomy: A Case Report and Literature Review

Article References: Hsieh, C.-E., Wu, P.-H., Su, C.-W., Ma, Y.-C., & Huang, H.-Y. (2026). Intra‐Abdominal Myxoid Leiomyosarcoma With PLAG1 Gene Rearrangement Following Prior Laparoscopic Myomectomy: A Case Report and Literature Review. Clinical Case Reports, 14(9), Article e73539. https://doi.org/10.1002/ccr3.73539

Image Credits: AI Generated

DOI: 10.1002/ccr3.73539

Keywords: myxoid leiomyosarcoma, PLAG1 gene rearrangement, leiomyosarcoma, myomectomy, fibroid surgery, peritoneal seeding, molecular diagnostics, FISH, immunohistochemistry, endometrial stromal sarcoma, trabectedin, soft tissue sarcoma